MultivisionDx appoints Michael Wittinger as new CEO


Helsinki, Finland
Michael Wittinger

Michael Wittinger, CEO of MultivisionDx

The MultivisionDx board of directors has appointed Michael Wittinger as the new CEO of the company. He joined the team on a full-time basis in October 2025, having previously worked as Chief Business Officer at the Austrian regulatory automation company Platomics.

“It’s a privilege to step into the CEO role at such an exciting moment for MultivisionDx,” says Michael. “Over the past year, I’ve seen first-hand the scientific excellence and determination of this team. Our next chapter is about turning the group’s discoveries into robust, regulation-ready diagnostic solutions that make a real impact for patients. I’m honoured to help lead that transformation.”

Michael brings extensive experience from the diagnostics, oncology and regulatory sectors to the new role, and has already worked with MultivisionDx as a part-time business consultant. In his previous position at Platomics, he played a key role in scaling the company from a 20-person start-up to a team of over 100, while establishing strategic partnerships with several of the world’s leading diagnostic manufacturers. He has more than 15 years of commercial and leadership experience in the life-science industry and holds a PhD in Microbiology and Genetics from the University of Vienna.

“As a founding team with a mostly academic scientific background, we knew we needed to strengthen the company with more commercial and business experience.” says Karolina Punovuori, MultivisionDx co-founder. “Having worked with Michael in the past year, it was clear that he was the right match for this important role, both in terms of expertise and cultural fit. We particularly value his strong professional background, experience in the diagnostics and regulatory sectors, and strong networks in the life sciences across Europe.” As the company’s founding CEO, Karolina will now step into the role of Chief Scientific Officer to guide the MultivisionDx scientific strategy.

As CEO, Michael’s main responsibilities will be to lead the company’s vision and commercial strategy, preparing the MultivisionDx diagnostic technology for regulatory approval and clinical validation in key European and US markets.

About MultivisionDx:

MultivisionDx is a cancer diagnostics company founded in 2025 as a spinout from the University of Helsinki, building decision-support tools that better match cancer patients with the best therapies for the biology of their disease. The technology is based on an award-winning scientific discovery from Sara Wickström’s lab at the University.

For further information contact us